Tags

Type your tag names separated by a space and hit enter

Oxcarbazepine in the maintenance treatment of bipolar disorder.
Cochrane Database Syst Rev 2008; (1):CD005171CD

Abstract

BACKGROUND

Some studies have suggested that oxcarbazepine has a role in preventing episode recurrence in bipolar affective disorder. This review attempted to investigate the existing evidence from randomised controlled trials for its use in the maintenance treatment of this illness.

OBJECTIVES

To review the efficacy of oxcarbazepine, relative to placebo and other agents, in the prevention of affective episodes of bipolar affective disorder. The efficacy of oxcarbazepine was considered in terms of episode recurrence, general and social functioning. Adverse effects, overall acceptability to participants and mortality were also considered.

SEARCH STRATEGY

CCDANCTR-Studies and CCDANCTR-References were searched on 7/11/2007. Medline, CENTRAL, EMBASE and PsycINFO were searched in March 2007. Specialist journals and conference proceedings were handsearched. Reference lists of relevant papers and major textbooks of affective disorder were checked. Authors, experts in the field and pharmaceutical companies were contacted requesting information on published or unpublished trials.

SELECTION CRITERIA

Randomised controlled trials comparing oxcarbazepine with placebo or alternative agents, where the stated intent of intervention was the maintenance treatment of bipolar affective disorder were sought. Participants with bipolar disorder, male and female, of all ages, were included.

DATA COLLECTION AND ANALYSIS

Data were extracted from the original reports individually by two review authors. The methodological quality of included studies was assessed individually by two review authors. The main outcomes were the efficacy of oxcarbazepine maintenance treatment in preventing or attenuating further episodes of bipolar affective disorder (including its efficacy in rapid cycling disorder), the acceptability of oxcarbazepine treatment to participants, the prevalence of side-effects, and mortality, if any, on oxcarbazepine treatment. Where appropriate, data concerning outcome measures and adverse effects were to be extracted from the studies and analysed using Review Manager software.

MAIN RESULTS

Two randomised controlled trials were found that met the methodological criteria for inclusion in the review. However, they did not report data with sufficient clarity to allow their confident extraction for inclusion in the meta-analysis. Findings from the two studies were presented descriptively.

AUTHORS' CONCLUSIONS

There is an insufficient methodologically rigorous evidence base to provide guidance on the use of oxcarbazepine in the maintenance treatment of bipolar disorder. Given the need for more efficacious therapeutic agents, there is a need for good quality randomised controlled trials examining the therapeutic potential of this and related agents in bipolar disorder.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

18254071

Citation

Vasudev, A, et al. "Oxcarbazepine in the Maintenance Treatment of Bipolar Disorder." The Cochrane Database of Systematic Reviews, 2008, p. CD005171.
Vasudev A, Macritchie K, Watson S, et al. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2008.
Vasudev, A., Macritchie, K., Watson, S., Geddes, J. R., & Young, A. H. (2008). Oxcarbazepine in the maintenance treatment of bipolar disorder. The Cochrane Database of Systematic Reviews, (1), p. CD005171. doi:10.1002/14651858.CD005171.pub2.
Vasudev A, et al. Oxcarbazepine in the Maintenance Treatment of Bipolar Disorder. Cochrane Database Syst Rev. 2008 Jan 23;(1)CD005171. PubMed PMID: 18254071.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oxcarbazepine in the maintenance treatment of bipolar disorder. AU - Vasudev,A, AU - Macritchie,K, AU - Watson,S, AU - Geddes,J R, AU - Young,A H, Y1 - 2008/01/23/ PY - 2008/2/7/pubmed PY - 2008/4/15/medline PY - 2008/2/7/entrez SP - CD005171 EP - CD005171 JF - The Cochrane database of systematic reviews JO - Cochrane Database Syst Rev IS - 1 N2 - BACKGROUND: Some studies have suggested that oxcarbazepine has a role in preventing episode recurrence in bipolar affective disorder. This review attempted to investigate the existing evidence from randomised controlled trials for its use in the maintenance treatment of this illness. OBJECTIVES: To review the efficacy of oxcarbazepine, relative to placebo and other agents, in the prevention of affective episodes of bipolar affective disorder. The efficacy of oxcarbazepine was considered in terms of episode recurrence, general and social functioning. Adverse effects, overall acceptability to participants and mortality were also considered. SEARCH STRATEGY: CCDANCTR-Studies and CCDANCTR-References were searched on 7/11/2007. Medline, CENTRAL, EMBASE and PsycINFO were searched in March 2007. Specialist journals and conference proceedings were handsearched. Reference lists of relevant papers and major textbooks of affective disorder were checked. Authors, experts in the field and pharmaceutical companies were contacted requesting information on published or unpublished trials. SELECTION CRITERIA: Randomised controlled trials comparing oxcarbazepine with placebo or alternative agents, where the stated intent of intervention was the maintenance treatment of bipolar affective disorder were sought. Participants with bipolar disorder, male and female, of all ages, were included. DATA COLLECTION AND ANALYSIS: Data were extracted from the original reports individually by two review authors. The methodological quality of included studies was assessed individually by two review authors. The main outcomes were the efficacy of oxcarbazepine maintenance treatment in preventing or attenuating further episodes of bipolar affective disorder (including its efficacy in rapid cycling disorder), the acceptability of oxcarbazepine treatment to participants, the prevalence of side-effects, and mortality, if any, on oxcarbazepine treatment. Where appropriate, data concerning outcome measures and adverse effects were to be extracted from the studies and analysed using Review Manager software. MAIN RESULTS: Two randomised controlled trials were found that met the methodological criteria for inclusion in the review. However, they did not report data with sufficient clarity to allow their confident extraction for inclusion in the meta-analysis. Findings from the two studies were presented descriptively. AUTHORS' CONCLUSIONS: There is an insufficient methodologically rigorous evidence base to provide guidance on the use of oxcarbazepine in the maintenance treatment of bipolar disorder. Given the need for more efficacious therapeutic agents, there is a need for good quality randomised controlled trials examining the therapeutic potential of this and related agents in bipolar disorder. SN - 1469-493X UR - https://www.unboundmedicine.com/medline/citation/18254071/Oxcarbazepine_in_the_maintenance_treatment_of_bipolar_disorder_ L2 - https://doi.org/10.1002/14651858.CD005171.pub2 DB - PRIME DP - Unbound Medicine ER -